161 results on '"Ruiz, Josel D."'
Search Results
2. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
3. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation
4. The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant
5. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma
6. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin
7. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
8. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
9. Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma
10. Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series
11. Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation
12. Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology
13. Abstract A48: Aging-related, Senescence-associated Secretory Phenotype and Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults
14. Prospective Geriatric Assessment and Geriatric Consultation in CAR T-cell Therapy for Older Lymphoma Patients
15. Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
16. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
17. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves
18. Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
19. Peri-Transplant Vitamin and Micronutrient Status in Allogeneic Hematopoietic Cell Transplantation
20. Utility of Routine Pulmonary Function Test after Autologous Hematopoietic Cell Transplantation in Lymphoma
21. Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation
22. The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
23. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
24. Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation
25. A Simplified Comorbidity Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
26. Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
27. Reflectance Confocal Microscopy Correlates with Histopathology in Nonsclerotic GvHD and Non-GvHD Rash after Day 100 Post Allogeneic Stem Cell Transplantation
28. Real-Time Reflectance Confocal Microscopy Features of Cutaneous Graft-Versus-Host Disease
29. High Rates of Residual Vaccine Titers at 1-Year Post CD19 Chimeric Antigen Receptor T Cell Therapy
30. Reflectance Confocal Microscopy Detects Pathologic Changes in Normal-Appearing Skin of Patients with Cutaneous Graft-Versus-Host Disease after Day 100 Post Allogeneic Stem Cell Transplantation
31. Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy
32. Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults
33. Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas
34. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin
35. The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients
36. Comparison of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin Lymphoma
37. Hematopoietic Recovery Following Chimeric Antigen Receptor T Cell (CAR T) Therapy in Hematological Malignancies
38. Renal Effects and Recovery in Patients Receiving Chimeric Antigen Receptor T Cell Therapy
39. Acute Kidney Injury in Allogeneic Hematopoietic Transplant Recipients
40. Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell
41. Time to Relapse and the Patterns of Relapse Are Prognostic for Post-Relapse Survival after CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma
42. Long-Term Survival in Patients with AML or MDS Relapsed after Allogeneic Hematopoietic Cell Transplantation: Importance of Second Cell Therapy
43. Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/Dl Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response (RR) at 1 Year in Light Chain (AL) Amyloidosis
44. Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores.
45. Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
46. Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
47. The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment
48. Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis
49. 502 - Utility of Routine Pulmonary Function Test after Autologous Hematopoietic Cell Transplantation in Lymphoma
50. 191 - Peri-Transplant Vitamin and Micronutrient Status in Allogeneic Hematopoietic Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.